Analysts Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Target Price at $12.38

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has been assigned a consensus recommendation of “Buy” from the five analysts that are covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $12.38.

CRVS has been the topic of a number of recent analyst reports. Mizuho raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Tuesday, January 14th. StockNews.com lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Finally, Oppenheimer raised their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Avity Investment Management Inc. grew its stake in Corvus Pharmaceuticals by 7.6% in the 4th quarter. Avity Investment Management Inc. now owns 29,680 shares of the company’s stock worth $159,000 after buying an additional 2,100 shares in the last quarter. Nwam LLC purchased a new stake in shares of Corvus Pharmaceuticals during the third quarter worth about $53,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Corvus Pharmaceuticals in the 4th quarter worth approximately $73,000. XTX Topco Ltd bought a new position in Corvus Pharmaceuticals in the 3rd quarter worth $74,000. Finally, Virtu Financial LLC bought a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter valued at about $83,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Trading Up 1.3 %

NASDAQ CRVS opened at $5.36 on Monday. Corvus Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $10.00. The company has a 50 day moving average of $6.26 and a 200-day moving average of $5.81. The company has a market cap of $344.42 million, a price-to-earnings ratio of -5.76 and a beta of 1.07.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.